ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

merck sharp dohme ltd - boceprevir - hepatitt c, kronisk - antivirale midler til systemisk bruk - victrelis er indisert for behandling av kronisk hepatitt-c (chc) genotype-1 smitte, i kombinasjon med peginterferon alfa og ribavirin hos voksne pasienter med kompensert leversykdom som tidligere ubehandlet eller som har mislyktes tidligere terapi.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

janssen-cilag international nv - simeprevir - hepatitt c, kronisk - antivirale midler til systemisk bruk - olysio er angitt i kombinasjon med andre legemidler til behandling av kronisk hepatitt c (chc) hos voksne pasienter. for hepatitt c-virus (hcv) genotypen bestemt aktivitet.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - hepatitt c, kronisk - antivirale midler til systemisk bruk - viekirax angis i kombinasjon med andre legemidler for behandling av kronisk hepatitt c (chc) hos voksne. for hepatitt c-virus (hcv) genotypen bestemt aktivitet.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

viatris limited - atenolol - tablett, filmdrasjert - 50 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

viatris limited - atenolol - tablett, filmdrasjert - 25 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

viatris limited - atenolol - tablett, filmdrasjert - 100 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

amdipharm ltd - hydralazinhydroklorid - tablett, drasjert - 25 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

sandoz - københavn - takrolimusmonohydrat - kapsel, hard - 1 mg